Potential Role of PROTAC ER Degraders in Therapy for HR-Positive

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

Listen now

Description

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here.

More Episodes

See all »

Oncology Today with Dr Neil Love

Published 11/15/24

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung Cancer

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here.

Published 11/15/24

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast Cancer

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here.

Published 11/15/24